Loading
If Pluvicto helps at first diagnosis, an alpha version might do more against microscopic disease, when tumour burden is smallest.
This speculative idea would give alpha-emitting PSMA therapy with actinium-225 at the first metastatic diagnosis of hormone-sensitive prostate cancer, alongside hormone therapy. Short-range alpha emission suits small-volume disease and is oxygen-independent, and early treatment avoids the PSMA heterogeneity of castration resistance; PSMAddition established beta-emitter therapy here. The hypothesis is deeper PSA nadirs and longer radiographic progression-free survival than lutetium-177 PSMA-617 at equal or lower salivary dose; salivary toxicity and actinium-225 supply are limiting. The test is a randomised phase 2 with PSMA PET-based dosimetry, salivary gland protection and the undetectable-PSA rate at one year as primary endpoint.
One of the most cited reviews Europe PMC returns for Lutetium-177 vipivotide tetraxetan in Prostate cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One of the most cited reviews Europe PMC returns for Lutetium-177 vipivotide tetraxetan in Prostate cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Shares Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments, Sequencing of Radium-223 and Lutetium-177 Vipivotide Tetraxetan: Maximizing the Benefit of Systemic Targeted Radiation Therapy in Metastatic Castration-Resistant Prostate Cancer, PSMAddition, Dosimetry.
Shares Actinium-225 PSMA agents, Alpha vs beta emitters, Lutetium-177 vipivotide tetraxetan, Targeted alpha therapy.
Shares Alpha vs beta emitters, Dosimetry, Targeted alpha therapy, Radioligand therapy (beta emitters).
Shares Alpha vs beta emitters, Dosimetry, Targeted alpha therapy.
Shares Alpha vs beta emitters, Dosimetry, Targeted alpha therapy, Radioligand therapy (beta emitters).
Shares Alpha vs beta emitters, Dosimetry, Radioligand therapy (beta emitters).
Shares Actinium-225 PSMA agents, Targeted alpha therapy, Radioligand therapy (beta emitters).
Shares Actinium-225 PSMA agents, Targeted alpha therapy, Prostate cancer.